Accelerating the evolution of veterinary care

Veterinarian, PhD (Clinical Science, Surgery) and Associate Professor in Veterinary Science, with focus on small animal surgery. Degree in veterinary medicine obtained at Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden, 1995. Odd has spent more than a decade in private practice in Sweden and England, where he worked almost exclusively with companion animals. During 2007-2012, he performed postgraduate studies to earn a PhD in surgery at the Faculty of Veterinary Medicine, SLU. Odd is currently Senior Lecturer in Translational Veterinary Medicine and a Fellow of the Academy of Translational Medicine Professionals (FAcadTM). His research is focused on development, testing and evaluation of innovative surgical techniques that aim to enable faster, easier and safer surgery with reduced risk of complications and shortened time for recovery. From a material perspective, the focus of Odd’s work is with resorbable polymers and ceramic materials, together with researchers at Uppsala University and KTH, Stockholm. He also performs development work for the medical device industry both in Uppsala and on the international arena. Odd’s teaching is mainly related to soft tissue surgery and endoscopic / minimally invasive techniques in companion animals.

Publication links:
Google Scholar 
PubMed

Anders Lundqvist has more than 35 years’ experience from senior roles in the life science industry including both pharmaceutical and medical device products. Initially Anders’ focus was on international business management in large corporations such as Baxter, Pharmacia & Upjohn and Bracco, which included overseas assignments in London, Hong Kong and Milan. 

In recent years he has used his experience and commercial mindset to drive the successful commercialization of life science startups where he has held senior roles including Nordic General Manager for ConvaTec as well as CEO of Ultrasonix and SciBase. In his most recent role, Lundqvist was CEO of OssDsign, a Swedish med-tech provider of next-generation bone regenerative products. 

Under Lundqvist’s leadership OssDsign saw an impressive development from an early-stage entrepreneurial start-up to becoming a fully commercialized company with market presence in Europe, US and Japan. During this period Lundqvist also managed several financing rounds including the listing of OssDsign on Nasdaq First North in Stockholm.

Håkan Engqvist is a certified Civil Engineer in material science, Senior Lecturer in Material Science and Professor in Applied Material Science at Ångström Laboratoriet at Uppsala University. Håkan has extensive research experience with particular focus on bioceramic materials as a replacement for hard tissue as well as on systems for pharmaceutical distribution. Håkan is the primary inventor of the Cavix proprietary bone graft substitute. He has founded several other companies and holds experience from board positions in a number of pharmaceutical and medtech companies.

Publication links:
Google Scholar
PubMed

Franck Forterre is a Professor of Clinical Veterinary Medicine at the Vetsuisse Faculty, University of Bern and a certified Diplomate of the European College of Veterinary Surgeons. He obtained his degree in veterinary medicine at Ecole National Veterinary Toulouse (1991), was a doctoral student and assistant in surgery/neurosurgery and the small animal surgery department of Ludwig Maximilian University of Munich (1991-1998), and deputy in neurosurgery at the Small Animal Clinic of the Free University Berlin (1999-2005). Franck has since 2005 been at the Vetsuisse Faculty, University of Bern where he is currently Head of the Small Animal Clinic and Small Animal Surgery Division. Franck's teaching is primarily related to small animal neurosurgery and orthopedic surgery. His research is focused on thoracolumbar disc disease, spinal trauma, and atlantoaxial instability, with biomechanical investigations and adapted implant development as the main research areas. Franck’s research is performed in a well-established international network involving specialists of all domains and has led to a high number of scientific contributions.

Publication links:
Research Gate
PubMed

Ulf Rosén has more than 35 years of proven experience in the pharmaceutical and medical technology industry including more than 20 years at startup and early-stage companies as investor, CEO and Board Member/Chairman. During his career, he has been directly involved in a number strategic investments and M&A activities. He was instrumental in pioneering the development of levodopa-carbidopa intestinal gel, which was commercialized in the EU member states as Duodopa®.
Such success led to its acquisition by Solvay Phamaceuticals and Abbott/AbbVie where Duodopa® was subsequently approved in the United States. 

Ulf was also Co-founder and CEO of Lobsor Pharmaceuticals, which was acquired by STADA/Britannia in September 2020. Previously, he held senior management positions in larger organizations including as CEO for Pharmacia & Upjohn Norway as well as Executive Vice President of Fresenius Kabi Global Nutrition Division. Ulf is a co-founder of, and currently serves as Chairman of the Board, of Intrance Medical Systems, a US-based company focused on the advancement of a next-generation therapy for advanced Parkinson's disease. Ulf also currently serves as independent board member of Acarix AB (listed at Nasdaq First North).

Anders Håkansson has more than 10 years’ operational experience from the big pharma industry. During his career he has also successfully founded several pharma companies, the first of which was founded in 2000 and sold in 2004. Following the sale of his second pharma company 2008, he founded his third and current pharma company Evolan AB, with a current turnover of >600 MSEK (2020). Anders currently serves as Chairman of the Board of Evolan AB.